BlackRock Inc. acquired a new stake in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 13,186,895 shares of the company's stock, valued at approximately $17,275,000. BlackRock Inc. owned 5.29% of Lineage Cell Therapeutics at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in LCTX. Fifth Third Bancorp bought a new position in Lineage Cell Therapeutics during the 1st quarter valued at $7,268,000. Marshall Wace LLP acquired a new stake in shares of Lineage Cell Therapeutics in the fourth quarter valued at $2,275,000. Goldman Sachs Group Inc. lifted its holdings in shares of Lineage Cell Therapeutics by 894.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,438,746 shares of the company's stock valued at $2,403,000 after buying an additional 1,294,070 shares during the period. Jane Street Group LLC boosted its stake in Lineage Cell Therapeutics by 494.7% during the fourth quarter. Jane Street Group LLC now owns 1,004,794 shares of the company's stock valued at $1,678,000 after buying an additional 835,831 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Lineage Cell Therapeutics by 6.2% during the third quarter. Vanguard Group Inc. now owns 9,006,930 shares of the company's stock valued at $15,222,000 after buying an additional 524,057 shares in the last quarter. Institutional investors own 62.47% of the company's stock.
Lineage Cell Therapeutics Stock Performance
Lineage Cell Therapeutics stock opened at $1.10 on Friday. The firm has a market cap of $278.20 million, a price-to-earnings ratio of -5.79 and a beta of 1.54. Lineage Cell Therapeutics, Inc. has a 1 year low of $1.00 and a 1 year high of $2.09. The firm's 50 day moving average price is $1.15 and its two-hundred day moving average price is $1.37.
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.03) EPS for the quarter, meeting analysts' consensus estimates of ($0.03). The company had revenue of $1.07 million during the quarter, compared to the consensus estimate of $1.84 million. Lineage Cell Therapeutics had a negative return on equity of 73.06% and a negative net margin of 246.58%. As a group, equities analysts predict that Lineage Cell Therapeutics, Inc. will post -0.08 EPS for the current fiscal year.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a "buy" rating on shares of Lineage Cell Therapeutics in a research report on Tuesday, July 14th. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $6.25.
Get Our Latest Stock Analysis on Lineage Cell Therapeutics
About Lineage Cell Therapeutics
(
Free Report)
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.
Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Lineage Cell Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lineage Cell Therapeutics wasn't on the list.
While Lineage Cell Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
